AGARWALEYE - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.3
| Stock Code | AGARWALEYE | Market Cap | 14,108 Cr. | Current Price | 445 ₹ | High / Low | 568 ₹ |
| Stock P/E | 239 | Book Value | 61.8 ₹ | Dividend Yield | 0.00 % | ROCE | 5.94 % |
| ROE | 1.31 % | Face Value | 1.00 ₹ | DMA 50 | 444 ₹ | DMA 200 | 454 ₹ |
| Chg in FII Hold | -0.12 % | Chg in DII Hold | 0.05 % | PAT Qtr | 14.6 Cr. | PAT Prev Qtr | 4.95 Cr. |
| RSI | 53.0 | MACD | 3.07 | Volume | 83,880 | Avg Vol 1Wk | 68,682 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | 1.57 | Debt to equity | 0.30 |
| 52w Index | 49.0 % | Qtr Profit Var | 80.3 % | EPS | 1.75 ₹ | Industry PE | 47.1 |
Analysis: Agarwal Eye Hospital (AGARWALEYE) shows weak fundamentals despite recent profit improvement. Current price (445 ₹) is near DMA 50 (444 ₹) and slightly below DMA 200 (454 ₹), indicating sideways momentum. RSI at 53.0 suggests neutral conditions, while MACD (3.07) supports mild bullishness. ROCE (5.94%) and ROE (1.31%) are weak, reflecting inefficiency. Quarterly PAT improved (14.6 Cr. vs 4.95 Cr.), with profit variation of 80.3% showing recovery. However, valuation is extremely stretched with P/E of 239 compared to industry PE of 47.1, and EPS of 1.75 ₹ highlights limited earnings strength. Debt-to-equity ratio of 0.30 is manageable but not negligible.
Optimal Entry Price: Around 430–440 ₹ (near support zone).
Exit Strategy if Holding: Consider booking profits near 460–470 ₹ unless momentum sustains above 475 ₹ resistance.
✅ Positive
- Quarterly PAT recovery (14.6 Cr. vs 4.95 Cr.) shows turnaround.
- Stock trading near DMA 50 indicates short-term stability.
- DII holdings increased (+0.05%), showing domestic investor confidence.
⚠️ Limitation
- Extremely high P/E (239) compared to industry average (47.1).
- Weak ROCE (5.94%) and ROE (1.31%).
- EPS of 1.75 ₹ highlights limited earnings strength.
- FII holdings decreased (-0.12%), showing reduced foreign interest.
📰 Company Negative News
- No major negative news reported, but stretched valuation and weak efficiency metrics are concerns.
🌟 Company Positive News
- Quarterly profit turnaround supports investor sentiment.
- Domestic institutional investors increased their stake.
🏭 Industry
- Industry P/E at 47.1 suggests Agarwal Eye trades at a steep premium.
- Healthcare sector remains resilient but valuations are often high.
📌 Conclusion
Agarwal Eye Hospital is a risky candidate for swing trading due to weak efficiency metrics and extreme valuation. Entry around 430–440 ₹ offers a safer setup, while exit near 460–470 ₹ is advisable unless momentum sustains above 475 ₹. Profit recovery and DII support are positives, but stretched valuation warrants cautious optimism.
Would you like me to expand this with a technical chart outlook, peer comparison, or sector growth analysis?